Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $24.67 Consensus PT from Brokerages

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has been assigned an average recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $22.56.

Several research analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Alliance Global Partners reaffirmed a “buy” rating on shares of Capricor Therapeutics in a report on Monday. Roth Capital dropped their price target on Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating on the stock in a report on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $24.00 price target (down previously from $77.00) on shares of Capricor Therapeutics in a report on Friday, July 11th. Finally, Wall Street Zen cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd.

Capricor Therapeutics Price Performance

CAPR opened at $7.24 on Monday. The company has a market capitalization of $330.72 million, a price-to-earnings ratio of -5.10 and a beta of 0.82. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The business has a 50 day moving average price of $10.28 and a two-hundred day moving average price of $11.98.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The company had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.42%. During the same period in the prior year, the company posted ($0.31) EPS. Equities analysts expect that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds have recently modified their holdings of CAPR. Bank of New York Mellon Corp increased its stake in shares of Capricor Therapeutics by 32.6% in the fourth quarter. Bank of New York Mellon Corp now owns 84,027 shares of the biotechnology company’s stock worth $1,160,000 after acquiring an additional 20,638 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Capricor Therapeutics by 51.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock worth $1,536,000 after purchasing an additional 37,868 shares in the last quarter. AlphaQuest LLC bought a new stake in Capricor Therapeutics in the fourth quarter worth $78,000. Swiss National Bank bought a new stake in Capricor Therapeutics in the fourth quarter worth $930,000. Finally, Intech Investment Management LLC bought a new stake in Capricor Therapeutics in the fourth quarter worth $228,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.